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Metabolic syndrome (MS) is a cluster of metabolic derangements associated with insulin resistance and an increased risk of
cardiovascular mortality. MS has become a major health concern worldwide and is considered to be the etiology of the current
epidemic of diabetes and cardiovascular disease. In addition to cardiovascular disease, the presence of MS is also closely associated
with other comorbidities including nonalcoholic fatty liver disease (NAFLD). The prevalence of MS in patients with cirrhosis
and end-stage liver disease is not well established and diﬃcult to ascertain. Following liver transplant, the prevalence of MS is
estimated to be 44–58%. The main factors associated with posttransplant MS are posttransplant diabetes, obesity, dyslipidemia,
and hypertension. In addition to developing NAFLD, posttransplant MS is associated with increased cardiovascular mortality that
is 2.5 times that of the age- and sex-matched individuals. Additionally, the presence of posttransplant MS has been associated with
rapid progression to fibrosis in individuals transplanted for HCV cirrhosis. There is an urgent need for well-designed prospective
studies to fully delineate the natural history and risk factors associated with posttransplant MS. Until then, early recognition,
prevention, and treatment of its components are vital in improving outcomes in liver transplant recipients.
1. Introduction
Metabolic syndrome (MS) is a cluster of metabolic derange-
ments associated with insulin resistance and an increased
risk of cardiovascular mortality. According to the Adult
Treatment Panel III definition (Table 1), MS is defined as the
presence of dyslipidemia, obesity, glucose intolerance, and
hypertension [1].
Metabolic syndrome has become a major health concern
worldwide and is considered to be the etiology of the current
epidemic of diabetes and cardiovascular disease. According
to the Framingham study, MS alone can predict at least 25%
of all new onset cardiovascular disease. The Third National
Health and Nutrition Examination Survey (NHANES) in
1999-2000 estimated the age-adjusted prevalence of MS in
the adult US population to be 24% and is projected to
increase further with the increasing prevalence of obesity
and diabetes [2]. In addition to cardiovascular disease, the
presence of MS is also closely associated with other comor-
bidities including nonalcoholic fatty liver disease (NAFLD),
cholelithiasis, polycystic ovary disease, and obstructive sleep
apnea. The aim of this paper is to discuss the importance and
impact of metabolic syndrome and its component in liver-
transplant recipients. Although only evidence that pertains
of liver transplantation will be discussed, similar metabolic
complications have been observed in patients undergoing
other solid organ transplants.
2. Nonalcoholic Fatty Liver Disease (NAFLD)
and Metabolic Syndrome
NAFLD is considered to be the hepatic manifestation of
MS and is defined as the presence of >5% deposition of
triglycerides in the liver in the absence of significant alcohol
consumption (<20–40 g/day for women and 40–80 g/day for
men). Up to 90% of patients with NAFLD have at least
1 feature of the MS, with 33% having all components of
the MS. The reported prevalence of NAFLD varies widely
depending on the population studied and modality used to
make the diagnosis but is estimated to be 6.3% to 33% in the
general population. Nonalcoholic steatohepatitis (NASH),
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the most aggressive phenotype of NAFLD, is characterized
by the presence of hepatocyte injury, cytologic ballooning,
and inflammation and has an estimated prevalence of 3–
5%. Unlike NAFLD, NASH is associated with a decreased
patient survival compared to the general population due to
the increased cardiovascular risk. Additionally, the presence
of NASH is associated with the increased risk of progression
to cirrhosis and a need for liver transplantation. A recent
analysis of the Scientific Registry of Transplant Recipients
(SRTRs) confirmed that the NASH as an indication for liver
transplant increased over 7-fold from 2001 to 2009, while no
other indication for liver transplantation increased over the
same time period [3]. Already being the 3rd most common
indication for liver transplant, it is poised to surpass HCV as
the leading indication for liver transplant in the near future
due to an unparalleled increase in features of MS.
3. Posttransplant Metabolic Syndrome (PTMS)
The prevalence of MS in patients with cirrhosis and end-
stage liver disease is not well established and diﬃcult to
be ascertained due to changes usually associated with end-
stage liver disease. The low systemic vascular resistance and
low lipid levels associated with chronic liver disease reduce
the likelihood that patients with cirrhosis would meet ATP
III criteria. Presence of ascites in cirrhotic patients can
further confound the diagnosis of obesity thereby, making
the diagnosis of MS in patients with cirrhosis diﬃcult.
However, there are data to suggest that the prevalence of MS
in cirrhosis and end-stage liver disease likely varies with the
etiology of liver disease and is likely higher in patients with
cryptogenic or NASH cirrhosis [4].
Liver transplantation is an eﬀective therapy for chronic
end-stage liver disease. Improvement in surgical techniques,
management of infectious complications, and immunosup-
pression have led to excellent long-term survival rates in
liver-transplant recipients. Consequently, death related to
metabolic consequences (cardiovascular disease and malig-
nancies) is becoming increasingly important as hepatic
etiologies of late post-liver-transplant death become less
common.
The limited number of studies evaluating the incidence
of PTMS in liver-transplant recipients has considerable
variability in the reported data due to diﬀering definitions of
MS used [5]. Recent studies estimate the prevalence of PTMS
to be 44–58% in liver-transplant recipients and is associated
with increased cardiovascular mortality (Table 2) [6, 7].
The relative risk of cardiovascular death in liver-transplant
recipients is 2.5 times that of the age- and sex-matched
individuals (Figure 1) [8]. Additionally, the presence of
PTMS has been associated with a rapid progression to
fibrosis in individuals transplanted for HCV cirrhosis [9].
This risk is even greater (30% versus 8%, P < 0.01) in
individuals with PTMS compared to those without it [6].
Since PTMS can aﬀect 1 out of 2 transplant recipients
and can account for up to 42% cardiovascular disease
related mortality, its impact on liver-transplant recipients
is immense [8, 10, 11]. The main factors associated with
Table 1: National cholesterol education program: Adult Treatment
Panel III criteria for metabolic syndrome.
Abdominal obesity
Waist circumference
>102 cm in men
>88 cm in women
Glucose intolerance Fasting plasma glucose ≥ 100mg/dL
(5.6mmol/L)
Hypertension Blood pressure ≥ 130/85mmHg or on
therapy for hypertension
Hypertriglyceridemia Serum triglycerides ≥ 150mg/dL or on
therapy for hypertriglyceridemia
Low HDL-C
Serum HDL-C < 40mg/dL (1mmol/L) in
men
Serum HDL-C < 50mg/dL (1.3mmol/L)
in women
Table 2: Prevalence of Posttransplant Metabolic Syndrome
(PTMS) and its components.
PTMS 45–58%
Obesity 21–43%
Hypertension 62–69%
Hypertriglyceridemia 66–85%
Low HDL-C 48–52%
Posttransplant de novo
fatty liver disease
18–40% (100% recurrence in patients
transplanted for cryptogenic cirrhosis at
5 years)
PTMS are posttransplant diabetes, obesity, dyslipidemia, and
hypertension (Table 2), which can result in posttransplant
NAFLD.
4. Posttransplant Diabetes Mellitus (PTDM)
Up to 60–80% of patients with cirrhosis may have glucose
intolerance and 20% may develop DM; it is due to pro-
found peripheral resistance, decreased glycogen synthesis,
and impaired glucose oxidation [12, 13]. Unfortunately,
up to third of patients will remain diabetic after liver
transplantation [14, 15]. Posttransplant diabetes mellitus
confers a twofold increased risk of cardiovascular and liver
related deaths in liver-transplant recipients [10]. Presence of
diabetes can also have detrimental impact on graft survival.
PTDM is associated with increased advanced graft fibrosis,
late onset hepatic artery thrombosis, recurrent or de novo
fatty liver disease, and acute and chronic rejection [14, 16–
18]. Additionally, the mortality and morbidity in liver-
transplant recipients is higher even when posttransplant
diabetes is transient [17, 19].
Earlier studies in liver-transplant recipients reported
the prevalence of PTDM 1 year after transplant from 13–
27% using the fasting plasma glucose of 140mg/dL as
the diagnostic criteria [5, 17, 20, 21]. However, using the
more recent diagnostic criteria of fasting plasma glucose of
126mg/dL, Laryea et al. reported the prevalence of PTDM to
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Figure 1: Complications of Posttransplant Metabolic Syndrome
(PTMS). CVD = cardiovascular disease, NAFLD = nonalcoholic
fatty liver disease.
be 61% [6]. In one study, 80% of new onset diabetes (NOD)
occurred within the first month after liver transplant and
only a small minority (12%) developed NOD after the 1st
year after transplant [14].
Although limited by retrospective data and small cohorts,
factors associated with PTDM include HCV and alcohol
related cirrhosis as indications for transplant (P < 0.05),
pretransplant DM (OR = 24.4, P < 0.01), male gender,
HCV infection, and steroid use (P < 0.05) [7, 16, 21, 22].
High doses of corticosteroids are an integral part of the early
immunosuppressive regiments in many transplant centers.
Corticosteroids lead to insulin resistance and diabetes by
decreasing insulin production, increasing gluconeogenesis,
and decreasing peripheral glucose utilization [23]. Decreas-
ing the dose of prednisone from 10mg to 5mg per day
reduced the prevalence of PTDM (P = 0.045) [5]. Similarly,
reducing the daily dose of prednisone from 13 ± 4mg at
1 year to 2 ± 4mg at 3 years leads to a 20% reduction in
the prevalence of PTDM [20]. In a recent meta-analysis,
the relative risk of diabetes (RR = 0.29, P < 0.001) was
attenuated when corticosteroids were replaced by another
immunosuppressive agent [24]. These eﬀects appear to
be transient as the prevalence of diabetes in post-liver-
transplant recipients reverts to that of patients on steroid-free
regiments once corticosteroids are discontinued [25].
Calcineurin inhibitors, cyclosporine (CsA) and Tacrol-
imus (FK506), are associated with an increased risk of
PTDM, with the incidence possibly being higher with the
use of Tacrolimus [7, 17, 21, 26]. The increased risk of
posttransplant diabetes associated with Tacrolimus (RR 1.38,
CI 1.01–1.86) use compared to CsA in liver transplant
recipient was confirmed in a recent Cochrane review [27].
The calcineurin inhibitors exert their diabetogenic eﬀects by
inhibiting pancreatic β-cell ability and diminishing insulin
synthesis and secretion [28]. Calcineurin inhibitors also
reduce peripheral glucose utilization leading to peripheral
insulin resistance.
Finally the data regarding the impact of Sirolimus, an
mTOR inhibitor, on posttransplant diabetes is conflicting.
Chronic mTOR inhibition has been associated with reduced
pancreatic β-cell mass, reduced hepatic insulin clearance,
and increased gluconeogenesis, thereby causing insulin resis-
tance [29]. On the other hand, activation of the mTOR
pathway via glucose leads to the inhibition of insulin receptor
substrate-2 (IRS-2), increase β-cell apoptosis and insulin
resistance [30]. Therefore, the impact of Sirolimus on PTDM
remains unclear.
5. Posttransplant Obesity
Obesity (body mass index (BMI) > 30 kg/m2) is a common
sequela of liver transplantation aﬀecting 21–42% liver-
transplant recipient [5, 31–33]. Risk factors for post-OLT
obesity include donor BMI, absence of acute rejection, and
steroid use [31]. Additionally, patients who are overweight
or obese before transplant will likely remain overweight or
obese after transplant. Furthermore, patients who were not
obese at the time of transplant, 16% became obese at 1 year
and 26% at 3 years [32].
Well-known side eﬀect of corticosteroid use is weight
gain and truncal obesity. Although corticosteroids have been
traditionally associated with greater posttransplant weight
gain, available literature suggests otherwise [32, 33]. This is
likely due to a reduction in dosing and duration of steroid
use as well as emergence of steroid-free or steroid-sparing
immunosuppressive regiments. Cyclosporine compared to
Tacrolimus was associated with an additional 2.3 kg gain 1
year after transplant [26]. However, these diﬀerences were
not significant 3 years after transplant.
6. Posttransplant Dyslipidemia
Dyslipidemia is common after transplant aﬀecting 45–69%
of liver-transplant recipients [7, 19, 34–37]. One study
reported the pretransplant prevalence of dyslipidemia rose
from 8% to 66% after liver transplant in patients who
were followed for over 14 months [35]. More specifi-
cally, prevalence of hypercholesterolemia and hypertriglyc-
eridemia increased from 2.9% and 18.2% before transplant
to 15.3% and 70% after transplant, respectively [38]. The
prevalence of low HDL after transplantation is reported to
be 48–52% [6, 39].
Risk factors of hypercholesterolemia in liver-transplant
recipients include pretransplant hypercholesterolemia,
cyclosporine, and corticosteroid use [35, 39]. Predictors
of posttransplant hypertriglyceridemia include cirrhosis
resulting fromHCV, HBV, alcohol, cryptogenic cirrhosis and
posttransplant renal insuﬃciency [35]. Although, long-term
therapy with corticosteroids can result in dyslipidemia, it is
unclear how corticosteroids impact long-term dyslipidemia
in posttransplant population [40]. Corticosteroids can lead
to dyslipidemia by increasing the hepatic production of
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lipids, increased production of very low-density lipoprotein
(VLDL) cholesterol, and decreased hepatic LDL reuptake.
Although both calcineurin inhibitors are also associ-
ated with posttransplant dyslipidemia and the relationship
between posttransplant dyslipidemia and cyclosporine is
more robust. Cyclosporine inhibits hepatic bile acid 26-
hydroxylase, which is thought to decrease reverse choles-
terol transport or transport of cholesterol into bile and
its subsequent elimination into the intestines [41]. Addi-
tionally, cyclosporine binds to LDL receptor and thereby
decreases LDL-cholesterol uptake [15, 39]. Conversion from
cyclosporine to Tacrolimus results in improvement in both
serum cholesterol and triglyceride levels but has no impact
on HDL cholesterol [42, 43].
Sirolimus is associated with posttransplant hypertriglyc-
eridemia and elevated serum LDL cholesterol. Sirolimus
alters the insulin-signaling pathway by increasing adipose
tissue lipase activity, decreasing lipoprotein lipase activ-
ity which results in increased hepatic triglyceride syn-
thesis, increased secretion of VLDL and thereby causing
hypertriglyceridemia [44]. Additionally, cyclosporine and
Sirolimus work synergistically to promote dyslipidemia and
should be avoided in patients with underlying dyslipidemia
[44, 45]. This synergistic eﬀect is not seen with Sirolimus and
Tacrolimus.
7. Posttransplant Hypertension
Since patients with cirrhosis, particularly decompensated
cirrhosis, have decreased systemic vascular resistance, hyper-
tension is only present in a small minority of patients before
transplant but can aﬀect 62–69% of liver-transplant recipi-
ents [5, 9, 45, 46]. Post-transplant hypertension may result
from increased renal vasoconstriction and impaired sodium
excretion induced by cyclosporine use and may occur less
frequently with Tacrolimus use [23, 46]. Patients treated
specifically with cyclosporine, the prevalence of hypertension
was 58–82%, while the incidence of posttransplant hyper-
tension was 31–38% in patients treated with Tacrolimus [26,
47, 48]. In animal models, cyclosporine generates interstitial
fibrosis without any significant decrease in renal blood flow
or structural arteriolar lesion, through early macrophage
influx and increased TGF-β expression. Additionally, since
cyclosporine-induced ischemia and tubulointerstitial injury
can occur independently, preventing renal injury with CsA
altogether could be diﬃcult [49]. Data regarding the use of
Sirolimus and posttransplant hypertension is still evolving
and no definitive statements can be made.
8. Posttransplant Nonalcoholic
Fatty Liver Disease
Nonalcoholic fatty liver disease is closely associated with
features of metabolic syndrome and likely represents the
hepatic manifestation of the metabolic syndrome. De novo
NALFD after transplant was initially reported in a retro-
spective study where 75% of patients transplanted for NASH
had fatty infiltration of the graft and 38% developed NASH
[50]. In patients transplanted for cryptogenic cirrhosis, time-
dependent risk of developing allograft steatosis was 100% by
five years [51]. Additionally, 25% of patients transplanted
for alcoholic and cholestatic liver disease developed fatty
liver disease. The risk of developing de novo NAFLD after
liver transplant is associated with pretransplant obesity, a
higher BMI at the time of the last biopsy, and a higher post-
transplant BMI [52, 53]. Patients with greater than 10%
increase in pretransplant BMI had a significantly higher risk
of developing de novo NAFLD compared to those without
weight gain. Unfortunately, the natural history of posttrans-
plant de novo fatty liver disease is currently unknown but it
is possible that post-transplant fatty liver disease contributes
to the increased cardiovascular mortality since NAFLD is
an independent risk factor CVD in noncirrhotic patients.
Well-designed prospective trials are needed to confirm this
assertion.
9. Conclusion
Metabolic syndrome and its components are common in
liver-transplant recipients and associated with increased car-
diovascular disease, fibrosis, de novo NAFLD after transplant
(Figure 1), and decreased patient and graft survival. There
is an urgent need for well-designed prospective studies to
fully delineate the natural history and risk factors associated
with PTMS. In the interim, early recognition, prevention,
and treatment of components of PTMS are vital in improving
outcomes in liver-transplant recipients.
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